Kalle Sigfridsson

Kalle Sigfridsson

Auto-generated profile, based on publicly available information

Kalle Sigfridsson

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2009 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
KSKalle Sigfridsson
Kalle Sigfridsson
ALAnders J. Lundqvist
Anders J. Lundqvist
MSMarie Strimfors
Marie Strimfors
Background: The exposure of UG558 was not good enough using traditional microsuspensions. Aim: The aim of this study was to find out whether nanosuspensions were a better choice compared with a microsuspension, for an acidic substance with a water solubility in the order of 2 μM (pH 6.8, small intestinal pH) and no permeability limitations. Methods: UG558 was ground by a planetary ball mill. The particle size was measured by laser diffraction and the stability of the particle sizes was followed. The pharmacokinetic parameters of UG558 administered as nanosuspension have been compared with those from microsuspension using rat as in vivo specie. Both formulations were administered orally. The nanosuspension was also administered intravenously. Results: The particle size of the nanosuspensions was about 190 nm and about 12 μm for the microsuspensions. At the administered doses, solutions were no alternative (e.g. due to limited solubility). Already at the lowest dose, 5 μmol/kg (5 ml/kg), a significant difference was observed between the two suspensions. These results were further confirmed at a high dose (500 μmol/kg, 5 mL/kg). Thus, the study demonstrated a clear correlation between particle size and in vivo exposures, where the nanosuspensions provided the highest exposure. Furthermore, no adverse events were observed for the substance nor the nanosuspension formulations (i.e., the particles) in spite of the higher exposures obtained with the nanoparticles. To make it possible to calculate the bioavailability, 5 μmol/kg doses of the nanosuspensions (5 ml/kg) were also administered intravenously. No adverse events were observed. Conclusions: The nanoparticles have a larger surface, resulting in faster in vivo dissolution rate, faster absorption, and increased bioavailability, compared to microparticles. The lower overall bioavailability observed at the high dose, compared with the low dose, was due to a combination of low dissolution rate, low solubility, and a narrow intestinal absorption window for UG558.

1 September 2007 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KSKalle Sigfridsson
Kalle Sigfridsson
SFSara Forssén
Sara Forssén
PHPaula Holländer
Paula Holländer
USUrban Skantze
Urban Skantze
JVJennie de Verdier
Jennie de Verdier

8 July 2010 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
KSKalle Sigfridsson
Kalle Sigfridsson
ANAnna Nordmark
Anna Nordmark
STStefanie Theilig
Stefanie Theilig
ALAnders Lindahl
Anders Lindahl
Aim: The aim of this study was to maximize the exposure of a model compound (MC) for forthcoming high-dose toxicological studies with the physical form of the original compound unaffected. Method: The two evaluated formulation approaches for the present poorly water-soluble compound were micro- and nanosuspensions. Results: The particle size was about 280 nm for the nanosuspensions and about 4 μm for the microsuspensions. The crystallinity and the crystalline form of the ground samples were conserved. The physical and the chemical stabilities of the two kinds of suspensions were unaffected during the investigated time period. The in vivo results of the study showed that the pharmacokinetic parameters investigated were comparable at the low-dose level (6 μmol/kg) for both formulations after single administration. However, at the two higher doses (60 and 300 μmol/kg), a significant difference in exposure was observed between the two suspensions with an improved exposure for smaller particles. After Day 7 of repeated administration, a significant difference in exposure was observed at all dose levels. The overall exposures were higher on Day 7, compared to the exposures on Day 1 (most significant for nanoparticles), due to an accumulation of compound in the body. Conclusions: The nanoparticles have a larger surface, resulting in faster in vivo dissolution rate, faster absorption, and increased bioavailability, compared to microparticles. The differences in systemic exposure of model compound, following oral administration of nano- or microparticles of the drug substance, are probably caused by differences in the in vivo dissolution rate and possibly further enhanced by saturation of the systemic elimination.

12 August 2010 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
KSKalle Sigfridsson
Kalle Sigfridsson
ALAnders J. Lundqvist
Anders J. Lundqvist
MSMarie Strimfors
Marie Strimfors
Aim: The aim of the present study was to find out if nanosuspensions were a better choice compared with microsuspensions, for the present substances with water solubility in the order of 2−3 μM (pH 6.8, small intestinal pH) and no permeability limitations. The ambition was also to understand what the higher solubility in the stomach for BA99 means in terms of absorption properties of the substance. Method: The pharmacokinetic parameters of a poorly soluble acid (AC88) and a poorly soluble base (BA99) administered orally as nanosuspensions have been compared with those from microsuspensions using rat as in vivo species. Results: A significant difference was observed between the two suspensions for AC88 already at the lowest dose, 5 μmol/kg (the particle size of the nanosuspensions and the microsuspensions was about 200 nm and 14 μm, respectively). These results were further confirmed at a high dose (500 μmol/kg). However, for BA99, there were no significant differences between the two formulations at any dose investigated (the particle size of the nanosuspensions and the microsuspensions was about 280 nm and 12 μm, respectively).Conclusions: The study demonstrated a clear correlation between particle size and in vivo exposures for an acidic compound, the nanosuspensions providing the highest exposure. For a basic compound, on the other hand, with the present properties and doses, a microsuspension was sufficient. In the latter case, the higher solubility at gastric pH, because of the basic pKa, limits the need for particle reduction.

1 May 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
KSKalle Sigfridsson
Kalle Sigfridsson
PSPia Skantze
Pia Skantze
USUrban Skantze
Urban Skantze
LSLena Svensson
Lena Svensson
LLLars Löfgren
Lars Löfgren
LLLennart Lindfors
Lennart Lindfors

1 August 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HRHanna A. Rydberg
Hanna A. Rydberg
MAMarianna Yanez Arteta
Marianna Yanez Arteta
SBStaffan Berg
Staffan Berg
LLLennart Lindfors
Lennart Lindfors
KSKalle Sigfridsson
Kalle Sigfridsson